Literature DB >> 9513707

Growth and differentiation of the normal mammary gland and its tumours.

P S Rudland1, R Barraclough, D G Fernig, J A Smith.   

Abstract

The mammary glands of non-pregnant rodents and humans consist of epithelial, intermediate stem and myoepithelial cells, and these have been isolated as cell lines in vitro. Growth factors produced by the myoepithelial cells, e.g. transforming growth factor alpha (TGF alpha) and basic fibroblast growth factor (bFGF), can stimulate the growth of the intermediate stem cells in vitro. One protein, p9Ka, a calcium binding regulatory protein, arises at an early stage of the differentiation of epithelial into myoepithelial cells in vitro and is associated with the cytoskeleton; another, cathepsin D, is a protease associated with this pathway in vivo. Unlike normal glands and benign lesions, malignant mammary carcinomas of rats and humans do not contain fully differentiated myoepithelial cells, and the resultant cell lines fail to differentiate completely into myoepithelial cells. Loss of the myoepithelial cells in some human invasive carcinomas may account, in part, for compensatory changes in the malignant cells. For example, overexpression of TGF alpha/ErbB-2 receptors may compensate for a decrease in TGF alpha, whereas ectopic production of bFGF and its receptors, and of p9Ka and cathepsin D, may help in tumorigenesis and in metastasis respectively. Thus compensation for, or retention of, molecules potentially involved in growth and/or differentiation by some human invasive carcinomas may be a mechanism by which a malignancy progresses.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9513707

Source DB:  PubMed          Journal:  Biochem Soc Symp        ISSN: 0067-8694


  9 in total

1.  Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties.

Authors:  M J Page; B Amess; R R Townsend; R Parekh; A Herath; L Brusten; M J Zvelebil; R C Stein; M D Waterfield; S C Davies; M J O'Hare
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

2.  Establishment and characterization of a caprine mammary myoepithelial cell line (CMMyoEC).

Authors:  A G Pantschenko; M R Barber; J Woodcock-Mitchell; S L Bushmich; T J Yang
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000-06       Impact factor: 2.416

Review 3.  Mammary epithelial stem cells: our current understanding.

Authors:  G Chepko; G H Smith
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-01       Impact factor: 2.673

4.  Orosphere assay: a method for propagation of head and neck cancer stem cells.

Authors:  Sudha Krishnamurthy; Jacques E Nör
Journal:  Head Neck       Date:  2012-07-13       Impact factor: 3.147

Review 5.  Joining S100 proteins and migration: for better or for worse, in sickness and in health.

Authors:  Stephane R Gross; Connie Goh Then Sin; Roger Barraclough; Philip S Rudland
Journal:  Cell Mol Life Sci       Date:  2013-06-30       Impact factor: 9.261

Review 6.  Environmental exposures and mammary gland development: state of the science, public health implications, and research recommendations.

Authors:  Ruthann A Rudel; Suzanne E Fenton; Janet M Ackerman; Susan Y Euling; Susan L Makris
Journal:  Environ Health Perspect       Date:  2011-06-22       Impact factor: 9.031

7.  Analysis of high fat diet induced genes during mammary gland development: identifying role players in poor prognosis of breast cancer.

Authors:  Raquel C Martinez-Chacin; Megan Keniry; Robert K Dearth
Journal:  BMC Res Notes       Date:  2014-08-18

Review 8.  Breast cancer stem cells: The role of sex steroid receptors.

Authors:  Pia Giovannelli; Marzia Di Donato; Giovanni Galasso; Erika Di Zazzo; Nicola Medici; Antonio Bilancio; Antimo Migliaccio; Gabriella Castoria
Journal:  World J Stem Cells       Date:  2019-09-26       Impact factor: 5.326

9.  S100A4 regulates cell motility and invasion in an in vitro model for breast cancer metastasis.

Authors:  S R Jenkinson; R Barraclough; C R West; P S Rudland
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.